Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 2/20 | 0.45 |
| ▸ | CCND3 | P30281 | 2/20 | 0.45 |
| ▸ | CCNK | O75909 | 1/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.45 |
| ▸ | CCNH | P51946 | 1/20 | 0.45 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24879043 | 0.96 | PTPN11 (0.52) | PTPN11MAPK3MAPK1CDK4CCND3 | |
| SCHEMBL31723366 | 0.96 | PTPN11 (0.52) | PTPN11MAPK3MAPK1CDK4CCND3 | |
| SCHEMBL24878927 | 0.95 | PTPN11 (0.54) | PTPN11MAPK3MAPK1 | |
| SCHEMBL31723348 | 0.94 | PTPN11 (0.51) | PTPN11MAPK3MAPK1 | |
| SCHEMBL27453103 | 0.94 | PTPN11 (0.54) | PTPN11MAPK3MAPK1 | |
| SCHEMBL24879308 | 0.93 | PTPN11 (0.53) | PTPN11MAPK3MAPK1CDK4CCND3 | |
| SCHEMBL30987302 | 0.92 | PTPN11 (0.51) | PTPN11MAPK3MAPK1 | |
| SCHEMBL24879187 | 0.91 | PTPN11 (0.51) | PTPN11MAPK3MAPK1 | |
| SCHEMBL24878881 | 0.90 | PTPN11 (0.53) | PTPN11MAPK3MAPK1CDK4CCND3 | |
| SCHEMBL24879146 | 0.90 | PTPN11 (0.52) | PTPN11MAPK3MAPK1CDK4CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | disclosed |
| EP-4368625-A1 | SHP2 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023282702-A1 | SHP2 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-01-12 | — | — | WO | disclosed |
| WO-2023282702-A1 | SHP2 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN2 | PTPN11 16/4885MAPK3 389/4885MAPK1 272/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | PTPN11 16/4885MAPK3 389/4885MAPK1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.